Skip to main content

Table 3 Safety and tolerability outcome

From: In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Adverse events AS + AQ n (%) AL n (%) p-value
Overall 88 (40.0) 87 (39.5) 1.00
Specific AEs
 Abdominal pain 18 (8.1) 17 (7.7) 1.00
 Digestive (nausea, vomiting, anorexia, diarrhea) 22 (10.0) 22 (10.0) 0.86
 Cough and rhinitis 23 (10.5) 28 (12.7) 0.55
 Bronchitis 12 (5.4) 13 (5.9) 1.00
 Fever 40 (18.2) 47 (21.4) 0.47
 Headache 16 (7.3) 21 (9.5) 0.49
 Other events 17 (7.7) 12 (5.5) 0.44
 SAE of any cause 1 (0.5) 1 (0.5) 1.00
  1. AE adverse event, SAE serious adverse event, AL artemether lumefantrine, ASAQ artesunate–amodiaquine